000056808 001__ 56808
000056808 005__ 20200221144335.0
000056808 0247_ $$2doi$$a10.3233/JAD-160325
000056808 0248_ $$2sideral$$a96362
000056808 037__ $$aART-2016-96362
000056808 041__ $$aeng
000056808 100__ $$aPérez-Grijalba, V.
000056808 245__ $$aValidation of Immunoassay-Based Tools for the Comprehensive Quantification of Aß40 and Aß42 Peptides in Plasma
000056808 260__ $$c2016
000056808 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056808 5203_ $$aRecent advances in neuroimaging and cerebrospinal fluid (CSF) biomarker assays have provided evidence of a long preclinical stage of Alzheimer''s disease (AD). This period is being increasingly targeted for secondary prevention trials of new therapies. In this context, the interest of a noninvasive, cost-effective amyloid-ß (Aß) blood-based test does not need to be overstated. Nevertheless, a thorough validation of these bioanalytical methods should be performed as a prerequisite for confident interpretation of clinical results. The aim of this study was to validate ELISA sandwich colorimetric ABtest40 and ABtest42 for the quantification of Aß40 and Aß42 in human plasma. The validation parameters assessed included precision, accuracy, sensitivity, specificity, recovery, and dilution linearity. ABtest40 and ABtest42 proved to be specific for their target peptide using Aß peptides with sequence similar to the target. Mean relative error in the quantification was found to be below 7.5 for both assays, with high intra-assay, inter-assay, and inter-batch precision (CV <9.0 on average). Sensitivity was assessed by determination of the limit of quantification fulfilling precision and accuracy criteria; it was established at 7.60 pg/ml and 3.60 pg/ml for ABtest40 and ABtest42, respectively. Plasma dilution linearity was demonstrated in PBS; however, dilution in a proprietary formulated buffer significantly increased the recovery of both Aß40 and Aß42 masked by matrix interactions, allowing a more comprehensive assessment of the free and total peptide levels in the plasma. In conclusion, both assays were successfully validated as tools for the quantification Aß40 and Aß42 in plasma.
000056808 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000056808 590__ $$a3.731$$b2016
000056808 591__ $$aNEUROSCIENCES$$b77 / 258 = 0.298$$c2016$$dQ2$$eT1
000056808 592__ $$a1.584$$b2016
000056808 593__ $$aClinical Psychology$$c2016$$dQ1
000056808 593__ $$aGeriatrics and Gerontology$$c2016$$dQ1
000056808 593__ $$aPsychiatry and Mental Health$$c2016$$dQ1
000056808 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000056808 593__ $$aNeuroscience (miscellaneous)$$c2016$$dQ2
000056808 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000056808 700__ $$aFandos, N.
000056808 700__ $$aCanudas, J.
000056808 700__ $$aInsua, D.
000056808 700__ $$aCasabona, D.
000056808 700__ $$aLacosta, A.M.
000056808 700__ $$aMontañés, M.
000056808 700__ $$aPesini, P.
000056808 700__ $$0(orcid)0000-0001-8485-7738$$aSarasa, M.$$uUniversidad de Zaragoza
000056808 7102_ $$11001$$2025$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Anatom.Anatom.Patológ.Com
000056808 773__ $$g54, 2 (2016), 751-762$$pJ. Alzheimer's dis.$$tJOURNAL OF ALZHEIMERS DISEASE$$x1387-2877
000056808 8564_ $$s268389$$uhttps://zaguan.unizar.es/record/56808/files/texto_completo.pdf$$yVersión publicada
000056808 8564_ $$s91993$$uhttps://zaguan.unizar.es/record/56808/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000056808 909CO $$ooai:zaguan.unizar.es:56808$$particulos$$pdriver
000056808 951__ $$a2020-02-21-13:46:49
000056808 980__ $$aARTICLE